CN117797102A - Botrytis cinerea polysaccharide tablet and preparation method thereof - Google Patents
Botrytis cinerea polysaccharide tablet and preparation method thereof Download PDFInfo
- Publication number
- CN117797102A CN117797102A CN202311443229.8A CN202311443229A CN117797102A CN 117797102 A CN117797102 A CN 117797102A CN 202311443229 A CN202311443229 A CN 202311443229A CN 117797102 A CN117797102 A CN 117797102A
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- botrytis cinerea
- tablet
- drying
- crude
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 95
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 94
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 94
- 241000123650 Botrytis cinerea Species 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000000463 material Substances 0.000 claims abstract description 25
- 238000002156 mixing Methods 0.000 claims abstract description 18
- 238000001035 drying Methods 0.000 claims abstract description 16
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 239000000853 adhesive Substances 0.000 claims abstract description 7
- 239000000945 filler Substances 0.000 claims abstract description 7
- 230000001070 adhesive effect Effects 0.000 claims abstract description 6
- 239000000314 lubricant Substances 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 35
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 229920003081 Povidone K 30 Polymers 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 241001474374 Blennius Species 0.000 claims description 13
- 235000019359 magnesium stearate Nutrition 0.000 claims description 13
- 238000007873 sieving Methods 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 12
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 8
- 239000011575 calcium Substances 0.000 claims description 8
- 229910052791 calcium Inorganic materials 0.000 claims description 8
- 229960000913 crospovidone Drugs 0.000 claims description 8
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 8
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 5
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000002390 rotary evaporation Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 7
- 230000036541 health Effects 0.000 abstract description 3
- 239000008187 granular material Substances 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 12
- 238000012216 screening Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 238000005469 granulation Methods 0.000 description 8
- 230000003179 granulation Effects 0.000 description 8
- 239000007779 soft material Substances 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- MYKOKMFESWKQRX-UHFFFAOYSA-N 10h-anthracen-9-one;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 MYKOKMFESWKQRX-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229940069328 povidone Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 241001465180 Botrytis Species 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- MRVNKBNZHOHVER-UHFFFAOYSA-N 2h-anthracen-1-one Chemical compound C1=CC=C2C=C3C(=O)CC=CC3=CC2=C1 MRVNKBNZHOHVER-UHFFFAOYSA-N 0.000 description 1
- 241001465358 Bryopsidales Species 0.000 description 1
- 241001290342 Caulerpa Species 0.000 description 1
- 241001339217 Caulerpa lentillifera Species 0.000 description 1
- 241001493811 Caulerpaceae Species 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to the technical field of marine organisms, in particular to a Botrytis cinerea polysaccharide tablet and a preparation method thereof. The Botrytis cinerea polysaccharide tablet is mainly prepared from Botrytis cinerea polysaccharide, a filling agent, an adhesive, a disintegrating agent, a lubricant and one or more other pharmaceutically acceptable auxiliary materials through mixing, granulating, drying and tabletting. The Botrytis cinerea polysaccharide tablet has the advantages of simple preparation method, stable product quality, convenient administration and certain health care effect.
Description
Technical Field
The invention relates to the technical field of marine organisms, in particular to a Botrytis cinerea polysaccharide tablet and a preparation method thereof.
Background
Botrytis cinerea (Caulerpa lentillifera) belongs to genus Botrytis (Caulerpa) of family Caulerpaceae of order Botrytis (Bryopsidales) belonging to the order Chlorophyta. The seaweed has rich nutrition, delicious taste and health care function, is called as long-life dish, is deeply favored by vast coastal residents, and is an economic seaweed with development prospect.
The main active ingredient in Botrytis cinerea is polysaccharide. The Botrytis cinerea polysaccharide has wide pharmacological activities of immunoregulation, anti-inflammation, anti-tumor, blood sugar reduction and the like. However, most of the current researches focus on extraction technology, polysaccharide structure analysis, activity research and the like of Botrytis cinerea polysaccharide, and development reports of polysaccharide application forms are lacking.
The tablet is one of the common clinical dosage forms, and has the advantages of being less influenced by factors such as external air, light, moisture and the like, good in chemical stability, convenient to carry and transport, easy to meet clinical needs and the like, so that the tablet is attractive to the public.
Disclosure of Invention
The invention aims to solve the technical problem of overcoming the defects of the prior art and provides a Botrytis cinerea polysaccharide tablet and a preparation method thereof.
In order to achieve the purpose of the invention, the following technical means are specifically adopted:
a Botrytis cinerea polysaccharide tablet is characterized by comprising an effective dose of Botrytis cinerea polysaccharide, a filling agent, an adhesive, a disintegrating agent, a lubricant and one or more other pharmaceutically acceptable auxiliary materials; the prescription is characterized by comprising the following prescription components in proportion: polysaccharide of Botrytis cinerea (30% -71%), anhydrous calcium hydrophosphate (10% -51%), povidone K30 (2% -10%), crospovidone (3% -9%), magnesium stearate (0.2% -1%), 75% ethanol (proper), and the rest is one or more compositions of sweetener, colorant, coating powder, etc.; the mass ratio of the Botrytis cinerea polysaccharide to the anhydrous calcium hydrophosphate is 0.8:1-1.6:1; the total amount of the above components is 100%.
The preparation method of the Botrytis cinerea polysaccharide comprises the following steps:
(1) Drying and powdering: drying the Botrytis cinerea with impurities removed, crushing, and sieving to obtain Botrytis cinerea powder;
(2) Mixing feed liquid: weighing crushed and sieved Botrytis cinerea powder, adding distilled water, and uniformly stirring to obtain a feed liquid mixture, wherein the feed liquid ratio is 1:50 g/ml;
(3) Extracting crude polysaccharide with water: extracting crude polysaccharide from the feed liquid mixture obtained in the step (2) for 2 times under the conditions of the extraction temperature of 80 ℃ and the extraction time of 2 hours, mixing the extracting solutions, and rotationally evaporating to obtain 1ml/g of crude polysaccharide extracting solution a of dry seaweed;
(4) Alcohol precipitation of crude polysaccharide: uniformly mixing the crude polysaccharide extract a obtained in the step (3) with 95% ethanol in a volume ratio of 1:4, standing at 4 ℃ for alcohol precipitation, and centrifuging at high speed after the completion of the precipitation to obtain a precipitate, and dissolving the precipitate into 1ml/g of crude polysaccharide extract b of dry seaweed;
(5) Sevage method removes protein: adding sevage reagent (chloroform: n-butanol=4:1) with 1/3 times volume into the crude polysaccharide extract b obtained in the step (4), oscillating at room temperature, centrifuging at high speed after the reaction is finished, and collecting supernatant; repeating the above steps for about 5-8 times until the solution is not precipitated, and concentrating by rotary evaporation to obtain crude polysaccharide extract c of 1ml/g dry seaweed;
(6) And (3) dialysis: dialyzing the polysaccharide extract c obtained in the step (5) at 4 ℃ in a dialysis bag with a molecular weight of 2500Da to remove the organic solvent and obtain a crude polysaccharide extract d;
(7) Freeze-drying and preserving: and (3) freeze-drying the crude polysaccharide extract d obtained in the step (6) to obtain the algal polysaccharide extract.
The preparation method of the pteridophyte polysaccharide tablet comprises the following steps: pulverizing Botrytis cinerea polysaccharide, anhydrous calcium hydrogen phosphate, povidone K30 and crospovidone by a pulverizer, and sieving; weighing the Botrytis cinerea polysaccharide, anhydrous calcium hydrophosphate, povidone K30 and crospovidone with the prescription amount, uniformly mixing, adding 75% ethanol for granulating, sieving, drying to the water content of 1-3%, adding the prescription amount of magnesium stearate, tabletting, controlling the hardness to be 80-100N and controlling the tablet weight to be 90-110mg.
Advantageous effects
The invention has the beneficial effects that:
(1) The invention provides a Botrytis cinerea polysaccharide tablet and a preparation method thereof, and provides an optional administration formulation for development and utilization of Botrytis cinerea.
(2) The Botrytis cinerea polysaccharide tablet prepared by the method has the advantages of simple preparation method, stable product quality, convenient administration and certain health care effect.
Detailed Description
The present invention will be further described with reference to specific examples, but it should not be construed that the scope of the subject matter of the present invention is limited to the following examples, and all techniques realized based on the foregoing disclosure are within the scope of the present invention.
The auxiliary materials in the following examples can be replaced by pharmaceutically acceptable auxiliary materials of the same type, or reduced or increased.
Example 1 method for determining polysaccharide content
The operation method for measuring the polysaccharide content by the sulfuric acid-anthrone method comprises the following steps:
A. preparing a standard solution: (1) anthrone reagent: precisely weighing 0.1g of anthrone, adding 80% concentrated sulfuric acid to dissolve, transferring to a brown volumetric flask, fixing volume to 100ml with 80% concentrated sulfuric acid, and shaking; it is ready for use (not more than 2 hours). (2) dextran standard solution: dextran was placed in a phosphorus pentoxide dryer, 0.1g was precisely weighed after 12 hours, and distilled water was used to determine the volume to 100ml to prepare a dextran standard solution of 1.0 mg/ml.
B. Drawing a standard curve: 0mL, 0.20mL, 0.40mL, 0.60mL, 0.80mL and 1.00mL dextran standard solutions were pipetted precisely into 10mL stoppered tubes and distilled water was used to make up to 1.0mL, 3 groups were prepared for each concentration. 4.0ml of anthrone-sulfuric acid solution was added, and the reaction solutions were mixed using a vortex shaker, and then the test tubes were placed in a boiling water bath to react for 10 minutes. The cold water bath was cooled to room temperature for 10min and the maximum desired wavelength was measured immediately at 626nm with an ultraviolet-visible spectrophotometer. And (3) establishing a standard curve by taking the mass of glucan as an abscissa and the absorbance as an ordinate.
C. Determination of sample content: taking 1.0ml of sample solution, measuring absorbance of Botrytis cinerea polysaccharide sample at 626nm according to the method, measuring for 3 times in parallel, and calculating polysaccharide content.
EXAMPLE 2 preparation of Botrytis cinerea polysaccharide
(1) Selecting algae: selecting fresh Botrytis cinerea as raw material, removing impurities such as weeds, silt and the like, and cleaning for standby;
(2) Drying and powdering: drying the Botrytis cinerea selected in the step (1) in the environment of 50 ℃ for 36-72 hours, taking out the dried seaweed, crushing, and sieving with a 60-mesh sieve to obtain Botrytis cinerea powder;
(3) Mixing feed liquid: weighing crushed and sieved Botrytis cinerea powder, adding distilled water, and properly stirring to obtain a feed liquid mixture, wherein the feed liquid ratio is 1:50 g/ml;
(4) Extracting crude polysaccharide with water: extracting crude polysaccharide from the feed liquid mixture obtained in the step (3) for 2 times under the conditions of the extraction temperature of 80 ℃ and the extraction time of 2 hours, mixing the extracting solutions, and rotationally evaporating to obtain 1ml/g of crude polysaccharide extracting solution a of dry seaweed;
(5) Alcohol precipitation of crude polysaccharide: uniformly mixing the crude polysaccharide extract a obtained in the step (4) with 95% ethanol in a volume ratio of 1:4, standing at 4 ℃ for 12h, centrifuging at a high speed of 5000r/min for 10min to obtain a precipitate, and dissolving into 1ml/g of crude polysaccharide extract b of dry seaweed;
(6) Sevage method removes protein: adding sevage reagent (chloroform: n-butanol=4:1) with volume 1/3 times into the crude polysaccharide extract b obtained in the step (5), oscillating for 20min at room temperature, centrifuging at high speed for 10min at 5000r/min after the reaction is finished, and collecting supernatant; repeating the above steps for about 5-8 times until the solution is not precipitated, and concentrating by rotary evaporation to obtain crude polysaccharide extract c of 1ml/g dry seaweed;
(7) And (3) dialysis: dialyzing the polysaccharide extract c obtained in the step (6) in a dialysis bag with a molecular weight of 2500Da at 4 ℃ for 48 hours to remove the organic solvent, thereby obtaining a crude polysaccharide extract d;
(8) Freeze-drying and preserving: and (3) freeze-drying the crude polysaccharide extract d obtained in the step (7) to obtain a seaweed polysaccharide extract, and then preserving the obtained freeze-dried powder at the temperature of minus 20 ℃.
Example 3 prescription screening of Botrytis cinerea polysaccharide tablets
(1) Investigation of hygroscopicity of auxiliary materials
The polysaccharide is easy to absorb moisture and needs to be improved by adding auxiliary materials which are not easy to absorb moisture.
The samples were placed in constant weight weighing flasks, placed in a desiccator with a humidity of 75% (controlled temperature of 20 ℃) and the mass of each material was weighed at 0, 2, 4, 8, 12, 24, 48 hours, respectively, the data were recorded and the moisture absorption was calculated.
Moisture absorption (%) = (Wt-W) 0 )/W 0 ×100％
Note that: wt is the mass of the sample after moisture absorption; w (W) 0 To dry the sample mass
The results are shown in the following table:
(2) Ultraviolet absorption determination of auxiliary materials
The content of the main drug polysaccharide in the finished tablet product needs to be detected through ultraviolet absorption reaction, and the selected auxiliary materials do not influence the content measurement of the main drug. The invention selects the common auxiliary materials of the tablet to be treated by an anthrone-sulfuric acid method, and the ultraviolet absorption condition of each auxiliary material is measured.
| Auxiliary materials | Sampling volume (mg) | Absorbance (D620) |
| Dextrin | 0.104 | 0.669 |
| Microcrystalline cellulose | 0.106 | 0.103 |
| Anhydrous calcium hydrogen phosphate | 0.106 | 0.002 |
| Povidone K30 | 0.106 | 0.003 |
| Carboxymethylcellulose sodium | 0.107 | 0.596 |
| Talc powder | 0.106 | 0.002 |
| Magnesium stearate | 0.101 | 0.003 |
| PEG6000 | 0.103 | 0.013 |
| Crosslinked povidone | 0.104 | 0.018 |
| Carboxymethyl starch sodium | 0.102 | 0.701 |
| Croscarmellose sodium | 0.107 | 0.626 |
Combining the properties of polysaccharide and the above investigation results of auxiliary materials, anhydrous calcium hydrophosphate, povidone K30, crosslinked povidone and magnesium stearate are selected as tablet auxiliary materials for subsequent prescription screening.
(3) Diluent quantity screening
The Botrytis cinerea polysaccharide has hygroscopicity, anhydrous calcium hydrophosphate is used as a filler, the filler is the main auxiliary material component, the dosage of the filler influences the moisture absorption rate of the polysaccharide tablet, the Botrytis cinerea polysaccharide and the auxiliary material are proportioned in different proportions, the moisture absorption rate measuring method is the same as the step (1) in the embodiment 3, and the optimal dosage proportion is screened according to the moisture absorption rate result.
As can be seen from the table, when the ratio of the polysaccharide to the diluent is 0.8:1, the moisture absorption rate is the lowest, and the ratio of the polysaccharide to the diluent is generally 0.25:1-1.2:1 in combination with the report of the preparation of the general natural polysaccharide extract tablet, the moisture absorption results show that the ratio has no influence on wet granulation tabletting, and the ratio of the polysaccharide to the diluent is finally 1.2:1 according to the principle of improving the content of the medicine as much as possible.
(4) Screening of wetting agents
The total amount of the prescription is set to be 10g initially, a certain amount of polysaccharide and auxiliary materials are weighed according to the proportion, the mixture is uniformly mixed, 7% of disintegrating agent is added, ethanol solutions with different concentrations of wetting agents are selected to carry out granulation investigation, manual granulation is adopted, the granulation state is unified as 'hand-held agglomeration, the powder is lightly touched', and the dosage of the wetting agents is determined by taking the granulation effect and the granule yield as indexes.
Mixing the main medicine and the auxiliary materials to prepare a soft material, and sieving the soft material with a 20-mesh sieve to obtain the granules with the percentage of the total weight of the sieved granules.
Granule yield (%) = weight of granules after sieving/total weight of material x 100%
| Sequence number | Ethanol (%) | Yield (%) | Granulating effect |
| 1 | 90 | 47.42 | Is not easy to pelletize, and has more fine powder |
| 2 | 85 | 55.48 | Is looser and has less granulation |
| 3 | 80 | 66.75 | Increased granulation |
| 4 | 75 | 84.42 | Granulating and sieving |
| 5 | 70 | 73.41 | Light sticking screen mesh, reduced granulation rate |
As can be seen from the table, when the ethanol concentration was 75%, the granulation effect was optimal, the formability was good, and 75% ethanol was selected as a wetting agent for tablet preparation.
(5) Screening of the adhesive usage
The total amount of the prescription is set to be 10g initially, a certain amount of polysaccharide and auxiliary materials are weighed and mixed uniformly, 7% of disintegrating agent and different amounts of povidone K30 and 75% of ethanol solution are added for granulating, the granules are finished after drying, and 1% of magnesium stearate is added for mixing and tabletting. Controlling the tablet hardness to be 90-110N, and determining the adhesive dosage by taking the grain yield and the disintegration time as indexes.
| Sequence number | Povidone K30 dosage (%) | Yield (%) | Disintegration time (min) |
| 1 | 2 | 79.04 | 6.20 |
| 2 | 4 | 91.11 | 6.57 |
| 3 | 6 | 76.50 | 7.83 |
| 4 | 8 | 66.09 | 13.50 |
| 5 | 10 | 67.66 | 13.85 |
As is clear from the table, when the amount of povidone K30 added was 4%, the yield was 91.11% at the highest, the disintegration time was satisfactory, and the amount of povidone K30 added was 4% as the amount of the binder for the polysaccharide tablet.
(6) Investigation of the moisture content of the granules
The total amount of the prescription is set to be 10g initially, the proportion of polysaccharide and diluent is determined, the adhesive and the disintegrating agent are obtained by screening, the soft material is prepared by using the amount of the disintegrating agent, and the soft material is placed in an oven for drying, so that the redundant moisture in the material is removed. Taking 3 batches of granules to examine different water contents at the same temperature of 60 ℃, respectively adding 1% of magnesium stearate into the granules dried to different water contents, mixing, tabletting, controlling the tablet hardness to be 90-110N, taking the disintegration time limit as an examination index, and observing the influence of the water contents of the granules on tablet molding.
| Sequence number | Preset moisture content (%) | Measured moisture content (%) | Disintegration time (min) | Drying time (min) |
| 1 | 2-3 | 2.47 | 8.83 | 10 |
| 2 | 1-2 | 1.85 | 7.92 | 20 |
| 3 | 0-1 | 0.89 | 7.82 | 60 |
The table shows that the water content of the granules meets the detection requirement of the tablet index within the range of 0-3%, when the water content of the granules is below 1%, the required drying time is longer, and finally the water content of the granules is selected to be 1-3%.
(7) Screening of disintegrant usage
The total amount of the prescription is set to 10g initially, the auxiliary materials with the determined dosage are added, the soft material is prepared by 75 percent of ethanol, sieved and granulated, and 1 percent of magnesium stearate is added for mixing and tabletting after drying. Controlling the tablet hardness to be 90-110N, examining the influence of the dosage of the crospovidone on the forming of the tablet, and evaluating the tablet by taking the disintegration time as an index.
| Sequence number | Disintegrant dosage (%) | Disintegration time (min) |
| 1 | 1 | 16.17 |
| 2 | 3 | 10.00 |
| 3 | 5 | 8.83 |
| 4 | 7 | 8.17 |
| 5 | 9 | 7.30 |
The disintegrant amount was selected to be 3% in combination with the results of the above table.
(8) Screening of lubricants
The total amount of the prescription is set to be 10g initially, auxiliary materials with determined dosages are added, 75% ethanol is used for preparing soft materials, sieving and granulating are carried out, and magnesium stearate with different dosages is added for mixing and tabletting after drying. The influence of the dosage of the lubricant magnesium stearate on the forming of the tablets is selected and examined, the tablet hardness is controlled to be 90-110N, and the tablets are evaluated by using the repose angle, the disintegration time limit and the tablet smoothness as indexes.
According to the screening result, 1% of magnesium stearate is selected to be added.
(9) Tablet hardness study
Hardness is an important influencing factor of tablet molding, and too low hardness can cause loosening of tablets and easy moisture absorption and deterioration; too high a hardness can result in delayed release of the active agent, affecting the efficacy. Therefore, according to the prescriptions and the process which are optimized in the earlier stage, the hardness of tablets with different hardness is inspected by adjusting the hardness range of the tablet press and taking the disintegration time and the friability as inspection indexes.
| Sequence number | Hardness (N) | Disintegration time (min) | Friability (%) |
| 1 | 40 | 5.07 | 1.14 |
| 2 | 60 | 7.01 | 0.72 |
| 3 | 80 | 7.40 | 0.60 |
| 4 | 100 | 7.50 | 0.57 |
| 5 | 120 | 9.45 | 0.54 |
Based on the above results, 80 to 100N was selected as the compression hardness of the tablet.
Based on the above screening, an exemplary prescription for tablets of the present invention was determined as:
| material | Proportion of | Action |
| Botrytis cinerea polysaccharide | 50.2％ | Main medicine |
| Anhydrous calcium hydrogen phosphate | 41.8％ | Filler (B) |
| Povidone K30 | 4％ | Adhesive agent |
| Crosslinked povidone | 3％ | Disintegrating agent |
| Magnesium stearate | 1％ | Lubricant |
| 75% ethanol | Proper amount of | Wetting agent |
According to the screening, the preparation process of the invention is determined as follows:
pulverizing Botrytis cinerea polysaccharide, anhydrous calcium hydrogen phosphate, povidone K30 and crospovidone, and sieving; weighing the Botrytis cinerea polysaccharide, anhydrous calcium hydrophosphate, povidone K30 and crospovidone with the prescription amount, uniformly mixing, adding 75% ethanol for granulating, sieving, drying to the water content of 1-3%, adding the prescription amount of magnesium stearate, tabletting, controlling the hardness to be 80-100N and controlling the tablet weight to be 90-110mg.
Example 4 quality evaluation of Botrytis cinerea polysaccharide tablet
(1) Weight difference
Batch 1,2,3 polysaccharide tablets were prepared, 20 tablets each were taken and weighed one by one, and the tablet weight difference was calculated.
The results are shown in the following table:
| lot number | Total sheet weight (g) | Average sheet weight (g) | Minimum (g) | Maximum value (g) | Limitation of sheet weight difference (%) |
| 1 | 2.0066 | 0.1003 | 0.0934 | 0.1063 | ±7.5％ |
| 2 | 1.9834 | 0.0992 | 0.0931 | 0.1055 | ±7.5％ |
| 3 | 1.9763 | 0.0988 | 0.0933 | 0.1049 | ±7.5％ |
As can be seen from the results of the table, the weight difference is satisfactory.
(2) Time limit of disintegration
As can be seen from the following table, the disintegration time limit meets the requirements.
(3) Friability degree of friability
As is evident from the following table, the friability meets the requirements.
| Lot number | Before testing (g) | After testing (g) | Weight loss (g) | Loss rate (%) |
| 1 | 6.7530 | 6.7133 | 0.0397 | 0.59 |
| 2 | 6.7323 | 6.6869 | 0.0454 | 0.67 |
| 3 | 6.6243 | 6.5914 | 0.0329 | 0.50 |
(4) Content determination
The content of the 3 lot products was determined by the content determination method examined by methodology, with the following results:
example 5 stability investigation of Botrytis cinerea polysaccharide tablet
Taking 3 batches of polysaccharide tablets, sealing and packaging the high-density polyethylene bottles, placing the tablets for 6 months under the accelerated test condition (the temperature is 40+/-2 ℃ and the relative humidity is 75% +/-5%), sampling the tablets at the end of the 0 th month, the 3 rd month and the 6 th month of the test period respectively, and detecting each stability index (appearance, moisture, hardness, disintegration time limit and content) of the tablets.
Lot number: 1
| Time (month) | Appearance of | Moisture (%) | Hardness (N) | Disintegration time (min) | Content of |
| 0 | White and smooth on the surface | 1.85 | 91 | 8.71 | 28.70 |
| 3 | White and smooth on the surface | 1.92 | 92 | 8.62 | 28.58 |
| 6 | White and smooth on the surface | 1.96 | 88 | 8.82 | 28.62 |
Lot number: 2
| Time (month) | Appearance of | Moisture (%) | Hardness (N) | Disintegration time (min) | Content of |
| 0 | White and smooth on the surface | 1.72 | 91 | 8.90 | 28.04 |
| 3 | White and smooth on the surface | 1.70 | 89 | 8.66 | 27.90 |
| 6 | White and smooth on the surface | 1.78 | 88 | 9.07 | 27.98 |
Lot number: 3
| Time (month) | Appearance of | Moisture (%) | Hardness (N) | Disintegration time (min) | Content of |
| 0 | White and smooth on the surface | 1.63 | 87 | 8.57 | 28.59 |
| 3 | White and smooth on the surface | 1.72 | 88 | 8.85 | 28.52 |
| 6 | White and smooth on the surface | 1.75 | 85 | 8.97 | 28.38 |
From the results, the Botrytis cinerea polysaccharide tablet prepared by the invention has stable quality.
The foregoing description of the preferred embodiments of the invention is not intended to limit the invention to the precise form disclosed, and any such modifications, equivalents, and alternatives falling within the spirit and scope of the invention are intended to be included within the scope of the invention.
Claims (3)
1. A Botrytis cinerea polysaccharide tablet is characterized by comprising an effective dose of Botrytis cinerea polysaccharide, a filling agent, an adhesive, a disintegrating agent, a lubricant and one or more other pharmaceutically acceptable auxiliary materials; the prescription composition is characterized by comprising the following components in proportion;
the rest components are one or more of sweetener, colorant, coating powder, etc.;
the mass ratio of the Botrytis cinerea polysaccharide to the anhydrous calcium hydrophosphate is 0.8:1-1.6:1;
the total amount of the above components is 100%.
2. The Botrytis cinerea polysaccharide tablet according to claim 1, which is characterized in that the preparation method of Botrytis cinerea polysaccharide is as follows:
(1) Drying and powdering: drying the Botrytis cinerea with impurities removed, crushing, and sieving to obtain Botrytis cinerea powder;
(2) Mixing feed liquid: weighing crushed and sieved Botrytis cinerea powder, adding distilled water, and uniformly stirring to obtain a feed liquid mixture, wherein the feed liquid ratio is 1:50 g/ml;
(3) Extracting crude polysaccharide with water: extracting crude polysaccharide from the feed liquid mixture obtained in the step (2) for 2 times under the conditions of the extraction temperature of 80 ℃ and the extraction time of 2 hours, mixing the extracting solutions, and rotationally evaporating to obtain 1ml/g of crude polysaccharide extracting solution a of dry seaweed;
(4) Alcohol precipitation of crude polysaccharide: uniformly mixing the crude polysaccharide extract a obtained in the step (3) with 95% ethanol in a volume ratio of 1:4, standing at 4 ℃ for alcohol precipitation, and centrifuging at high speed after the completion of the precipitation to obtain a precipitate, and dissolving the precipitate into 1ml/g of crude polysaccharide extract b of dry seaweed;
(5) Sevage method removes protein: adding sevage reagent (chloroform: n-butanol=4:1) with 1/3 times volume into the crude polysaccharide extract b obtained in the step (4), oscillating at room temperature, centrifuging at high speed after the reaction is finished, and collecting supernatant; repeating the above steps for about 5-8 times until the solution is not precipitated, and concentrating by rotary evaporation to obtain crude polysaccharide extract c of 1ml/g dry seaweed;
(6) And (3) dialysis: dialyzing the polysaccharide extract c obtained in the step (5) at 4 ℃ in a dialysis bag with a molecular weight of 2500Da to remove the organic solvent and obtain a crude polysaccharide extract d;
(7) Freeze-drying and preserving: and (3) freeze-drying the crude polysaccharide extract d obtained in the step (6) to obtain the algal polysaccharide extract.
3. The Botrytis cinerea polysaccharide tablet of claim 1, wherein the preparation method comprises the following steps: pulverizing Botrytis cinerea polysaccharide, anhydrous calcium hydrogen phosphate, povidone K30 and crospovidone, and sieving; weighing the Botrytis cinerea polysaccharide, anhydrous calcium hydrophosphate, povidone K30 and crospovidone with the prescription amount, uniformly mixing, adding 75% ethanol for granulating, sieving, drying to the water content of 1-3%, adding the prescription amount of magnesium stearate, tabletting, controlling the hardness to be 80-100N and controlling the tablet weight to be 90-110mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311443229.8A CN117797102A (en) | 2023-10-27 | 2023-10-27 | Botrytis cinerea polysaccharide tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311443229.8A CN117797102A (en) | 2023-10-27 | 2023-10-27 | Botrytis cinerea polysaccharide tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117797102A true CN117797102A (en) | 2024-04-02 |
Family
ID=90418782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311443229.8A Pending CN117797102A (en) | 2023-10-27 | 2023-10-27 | Botrytis cinerea polysaccharide tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117797102A (en) |
-
2023
- 2023-10-27 CN CN202311443229.8A patent/CN117797102A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101985644B (en) | Momordica charantia polypeptide, preparation method and application thereof | |
| CN101214282B (en) | Method for extracting active component from cistanche salsa | |
| CN102397342B (en) | Golden buckwheat rhizome extract, pharmaceutical preparation containing golden buckwheat rhizome extract and preparation method thereof | |
| CN111973642A (en) | Ginseng granules and preparation method thereof | |
| CN110301640A (en) | Bitter buckwheat flavone dry powder and its preparation have auxiliary hyperglycemic function health care product purposes | |
| CN117797102A (en) | Botrytis cinerea polysaccharide tablet and preparation method thereof | |
| CN110711212B (en) | Astragalus root-paecilomyces cicadae fermentation mycoplasm and application thereof | |
| CN107184661A (en) | The direct oral traditional Chinese medicine medicine materical crude slice of vinegar tetrahydropalmatine | |
| Tumwesigye et al. | Engineered food supplement excipients from bitter cassava for minimisation of cassava processing waste in environment | |
| CN1739666A (en) | Capsule prepn for treating laryngopharyngitis and tonsillitis and its prepn process | |
| Adeyanju et al. | Characterization and Utilization of Sweitenia mycrophylla Exudate Gum as an Excipient in Drug Formulation. | |
| CN102018736A (en) | Natural indigo decoction piece and preparation method thereof | |
| CN114288256A (en) | Preparation method of sugar-free tablet for treating enteritis | |
| CN112076175A (en) | Cordyceps militaris polysaccharide effervescent tablet, and preparation method and application thereof | |
| Emeje et al. | Physicochemical and drug release properties of microcrystalline cellulose derived from Musa balbisiana | |
| CN108578374B (en) | Chitosan oligosaccharide granules and preparation method thereof | |
| CN115590909B (en) | Radix ranunculi ternati formula particle and preparation method thereof | |
| Mupparaju et al. | Formulation and evaluation of dolutegravir sodium solid dispersions and fast dissolving tablets using poloxamer-188 and jackfruit seed starch as excipients | |
| CN117180337B (en) | Preparation method of Mongolian medicine raspberry wood formula particles and fingerprint construction method thereof | |
| CN114099446B (en) | Ginseng stem and leaf total saponin preparation and preparation method thereof | |
| Putra et al. | Formulation of Mucoadhesive Tablets with Fully Gelatinized Modified Daluga (Cyrtosperma Merkusii) Matrix Using Simplex Lattice Design Method | |
| CN111732672B (en) | Okra polygalacturonic acid with uric acid reducing effect and preparation method and application thereof | |
| Murthy et al. | Development of Metoprolol Tartrate Sustained Release Formulations by using Modified Starches | |
| CN1883601A (en) | Chinese medicinal capsule for treating inflammation and method for preparing same | |
| CN1977949A (en) | Chinese medicine particle preparation for relieving cough and eliminating phlegm and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |